Evogene Names aGVHD as Target for Internal Drug Discovery Program
Evogene named acute graft-versus-host disease as the target indication for its internal AI-driven drug discovery program.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Evogene Names Acute Graft-Versus-Host Disease as Drug Program Target
Evogene said acute graft-versus-host disease is the target indication for its internal AI-driven drug discovery program.